T Cell and Immune Checkpoint in Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (15 January 2023) | Viewed by 5718
Special Issue Editors
Interests: cancer therapy; immune checkpoint; immunotherapy; immune suppression
Special Issues, Collections and Topics in MDPI journals
2. Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA
Interests: cancer immunotherapy; immune checkpoint; tumor cell; T cell
Special Issue Information
Dear Colleagues,
Immunotherapy, specifically immune checkpoint blockers (ICBs), has revolutionized the way that we treat cancer and, along with surgery, chemotherapy, and radiotherapy, it has recently formed the fourth pillar of cancer care. ICB therapy had significant benefits for patients with peripheral tumors, but this outcome did not translate to all patients and CNS tumors. Moreover, inherent and acquired resistance to ICB is an important issue that is currently being investigated in preclinical and clinical settings. The durability of response and drivers of resistance versus response is another important issue that has recently been raised within the scientific community. Our Special Issue aims to gather a comprehensive set of reviews to inform our readership, which focus on the following topics:
- Appropriate preclinical models that have informed the trials and discussions on model selections and their consequences;
- The responses of predictors and biomarkers to ICB therapy;
- Combinatorial therapies that potentiate ICB;
- Causes and consequences of the inherent and acquired resistance to ICB;
- Therapeutic modalities and technologies that can address resistance to ICB;
- The drivers of durable responses after ICB therapy.
Dr. Zohreh Amoozgar
Dr. Rong En Tay
Dr. Rana Jahanban-Esfahlan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- immune checkpoint blockers (ICBs)
- ICB therapy
- chemotherapy
- radiotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
